Totally understand that the FDA is in control and I totally agree that it is the about the science and the impact on the indications, I guess my question is more about whether or not Anavex looks to push up review timelines based on the various options that I mentioned or things like FTD or priority review voucher? Or even if they could use those options potentially.
Market Data 
Markets 
AI
